MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that under the Australian Government’s Research and Development Income Tax Concession incentive program, the Company has received a cash refund of AUD $306,154 for eligible research and development expenditure incurred during the 2021 Financial Year.
This release has been authorized by the directors of Immuron Limited.
| COMPANY CONTACT:
Dr Jerry Kanellos, Ph.D. |
US INVESTOR CONTACT
Dave Gentry, CEO |
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.
For more information visit: http://www.immuron.com
DUBLIN--(BUSINESS WIRE)--The "Global Medical Device Connectivity Market: Analysis By Product & Services, By Technology, By…
VANCOUVER, WA / ACCESSWIRE / March 22, 2024 / At just eight years old, Zeke…
GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB…
OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or…
WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere…